Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab combinations versus platinum doublet chemotherapy in first-line advanced NSCLC with PD-L1 <50%
2017-001311-36Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Cemiplimab plus full chemotherapy, Cemiplimab plus limited chemotherapy plus ipilimumab and Standard-of-care platinum-based doublet chemotherapy (3 arms). Primary endpoint: Progression-free survival. Started Mar 2018; status: active.
02
Drugs
cemiplimabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-001311-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001311-36.